Xipiro seeks $3M to fund novel molecule in ROP

Rare Diseases

Xipiro developed a molecule, pNaKtide, that acts on a Master Control Switch to halt the generation of ROS. pNaKtide can be capitalized across a series of indications. With initial focus on ROP, Xipiro is raising to fully fund IND-enabling studies.

Project Team

Laura Shapiro
Laura Shapiro
Maosheng Duan
Maosheng Duan
Rajit  Malhotra
Rajit Malhotra
Joseph  Shapiro
Joseph Shapiro
Ryan Beal
Ryan Beal


Xipiro, Inc.
Xipiro, Inc.

Project Status

Clinical Stage
Patent Status
Patent approved

Funding Opportunity

Opportunity type
Funding requested
Funding allocated


Science Background: https://www.dropbox.com/s/twteo0v4sp83j6h/Xipiro%20Science%20Foundation.pdf?dl=0 Background Articles: https://www.dropbox.com/s/8kabigze9cph630/Articles.zip?dl=0 IOVS Article: https://iovs.arvojournals.org/article.aspx?articleid=2772032

Project Details

Pitch Deck: https://www.dropbox.com/s/jfzk5ew85zhloa4/XIPIRO%20Intro.pdf?dl=0

Project Timeline

  • Extended Seed Round (with potential tranche)

    Required Funding$3,000,000
    Duration6 Months

    Orphan Indication Status + Priority Review Voucher Applications: $100k MILESTONE (+6 months): Orphan Indication Status granted and acceptance into the PRV program ---- Manufactured GMP-Batch of XIP-100: $300k MILESTONE (+3 months): Completed GMP batch of XIP-100 ---- IND-Enabling Studies: $2.5 million MILESTONE (+18 months): Completed toxicology, bioanalysis methods and pharmacology studies and ability to submit to FDA for Phase I Clinical Trial clearance